[{"data":1,"prerenderedAt":156},["ShallowReactive",2],{"drug-olodaterol":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":35,"contraindications":60,"warnings":69,"renal":77,"monitoring":78,"interactions":79,"review":80,"examples":83,"atc":90,"iran":92,"usApproval":99,"links":105,"populations":120},"olodaterol",1,{"fa":7,"en":8},"اولوداترول","Olodaterol","respiratory",{"fa":11,"en":12},"آگونیست بتا-۲ طولانی‌اثر (LABA)","Long-acting beta2-agonist (LABA)",[14],{"name":15,"market":16},"Striverdi Respimat","US",[18,19,7],"striverdi","استریوردی",[21],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"respimat","inhaler","inhaled","2.5 mcg per actuation (Respimat); 1 dose = 2 actuations",{"amount":27,"unit":28,"perUnit":29},2.5,"mcg","actuation",[16],[32],{"source":33,"section":34},"fda-striverdi","3",[36],{"id":37,"disease":37,"label":38,"population":41,"type":45,"unit":28,"dose":46,"refs":48,"notes":51},"copd",{"fa":39,"en":40},"نگهدارنده COPD — دو استنشاق (۵ mcg) یک بار در روز","COPD maintenance — 2 inhalations (5 mcg) once daily",{"minAge":42},{"value":43,"unit":44},18,"year","fixed",{"perDose":47,"dosesPerDay":5},5,[49],{"source":33,"section":50},"2",[52],{"text":53,"refs":56},{"fa":54,"en":55},"بیش از ۲ استنشاق در ۲۴ ساعت نه. برای آسم اندیکاسیون ندارد.","Not more than 2 inhalations every 24 h. Not indicated for asthma.",[57,58],{"source":33,"section":50},{"source":33,"section":59},"4",[61],{"id":62,"severity":63,"text":64,"refs":67},"asthma","block",{"fa":65,"en":66},"LABA بدون کورتیکواستروئید استنشاقی در آسم.","LABA without an inhaled corticosteroid in asthma.",[68],{"source":33,"section":59},[70],{"text":71,"refs":74},{"fa":72,"en":73},"رویدادهای جدی مرتبط با آسم؛ برای حمله حاد نیست؛ مصرف بیش از حد خطرناک است؛ برونکواسپاسم متناقض؛ اثرات قلبی؛ هیپوکالمی و هیپرگلیسمی.","Serious asthma-related events; not for acute episodes; excessive use is dangerous; paradoxical bronchospasm; cardiovascular effects; hypokalaemia and hyperglycaemia.",[75],{"source":33,"section":76},"5",[],[],[],{"status":81,"reviewer":82,"date":82},"unverified",null,[84],{"regimen":37,"formulation":22,"input":85,"expect":88},{"ageYears":86,"weightKg":87},65,70,{"perDose":47,"tabletsPerDoseRounded":89},2,[91],"R03AC19",{"status":93,"refs":94},"not-found",[95],{"source":96,"section":97,"url":98},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=Olodaterol",{"kind":100,"refs":101,"id":104},"NDA",[102],{"source":33,"section":103},"SPL approval \u002F marketing category","NDA203108",[106,109,113,117],{"kind":107,"url":108,"label":104},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=203108",{"kind":110,"url":111,"label":112},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=5d9a5433-857e-44ea-b3d6-2a400ca0cef5","FDA Striverdi Respimat",{"kind":114,"url":115,"label":116},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa615019.html","Olodaterol Oral Inhalation",{"kind":118,"url":119,"label":91},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=R03AC19",{"pregnancy":121,"lactation":130,"pediatric":138,"geriatric":147},{"level":122,"text":123,"quote":126,"refs":127},"caution",{"fa":124,"en":125},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no adequate and well-controlled clinical studies with STRIVERDI RESPIMAT in pregnant women to inform of drug-associated risk of adverse pregnancy-related outcomes.",[128],{"source":33,"section":129},"8.1",{"level":122,"text":131,"quote":134,"refs":135},{"fa":132,"en":133},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no available data on the presence of olodaterol in human milk, the effects on the breastfed infant, or the effects on milk production.",[136],{"source":33,"section":137},"8.2",{"level":139,"text":140,"quote":143,"refs":144},"not-established",{"fa":141,"en":142},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","The safety and effectiveness of STRIVERDI RESPIMAT in the pediatric population have not been established.",[145],{"source":33,"section":146},"8.4",{"level":148,"text":149,"quote":152,"refs":153},"ok",{"fa":150,"en":151},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in effectiveness were observed, and in the 1-year pooled data, the adverse drug reaction profiles were similar in the older population compared to the patient population overall.",[154],{"source":33,"section":155},"8.5",1792191558089]